Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K7 | O14733 | 1/20 | 0.33 |
| ▸ | S100A4 | P26447 | 1/20 | 0.33 |
| ▸ | CDC25A | P30304 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20626665 | 0.84 | MAP2K7 (0.39) | MAP2K7S100A4CDC25ACDC25BGSK3B | |
| SCHEMBL11885272 | 0.76 | MAP2K7 (0.42) | MAP2K7S100A4CDC25ACDC25BGSK3B | |
| SCHEMBL11886044 | 0.75 | PTGS2 (0.31) | MAP2K7CDC25ACDC25B | |
| SCHEMBL845296 | 0.66 | — | — | |
| SCHEMBL3470127 | 0.65 | — | — | |
| SCHEMBL1164153 | 0.63 | — | — | |
| SCHEMBL15203012 | 0.59 | S100A4 (0.43) | MAP2K7S100A4CDC25ACDC25B | |
| SCHEMBL11885266 | 0.56 | S100A4 (0.39) | S100A4GSK3BKDM4E | |
| SCHEMBL1164258 | 0.56 | CDC25A (0.47) | MAP2K7S100A4CDC25ACDC25BKDM4E | |
| SCHEMBL3469703 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160176942-A1 | Reversible Covalent Linkage of Functional Molecules | UCL BUSINESS PLC (GB) | 2016-06-23 | — | — | US | disclosed |
| US-20160176942-A1 | Reversible Covalent Linkage of Functional Molecules | UCL BUSINESS PLC (GB) | 2016-06-23 | — | — | US | disclosed |
| US-9295729-B2 | Reversible covalent linkage of functional molecules | UCL BUSINESS PLC (GB) | 2016-03-29 | — | — | US | disclosed |
| US-20120190579-A1 | Functionalisation of Solid Substrates | UCL BUSINESS PLC (GB) | 2012-07-26 | — | — | US | disclosed |
| US-20120190814-A1 | Thiol Protecting Group | UCL BUSINESS PLC (GB) | 2012-07-26 | — | — | US | disclosed |
| US-20120190124-A1 | Reversible Covalent Linkage of Functional Molecules | UCL BUSINESS LTD (GB) | 2012-07-26 | — | — | US | disclosed |
| WO-2011018613-A1 | FUNCTIONALISATION OF SOLID SUBSTRATES | UCL BUSINESS PLC (GB) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190124-A1 | Reversible Covalent Linkage of Functional Molecules | F12, F13A1, F2 | MAP2K7 4326/4885S100A4 2318/4885CDC25A 656/4885 |
| US-20120190579-A1 | Functionalisation of Solid Substrates | XDH, SPR, DAO | MAP2K7 745/4885S100A4 3076/4885CDC25A 1637/4885 |
| US-20160176942-A1 | Reversible Covalent Linkage of Functional Molecules | F12, F13A1, F2 | MAP2K7 4326/4885S100A4 2318/4885CDC25A 656/4885 |
| US-20120190814-A1 | Thiol Protecting Group | TXN, PRDX3, TST | MAP2K7 4469/4885S100A4 1824/4885CDC25A 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.